Curiato

Curiato is a digital health platform that is leveraging biosensing and AI to deliver patient data and insights directly from the surface of the bed to power an ecosystem of applications such as pressure injuries, heart failure, infectious disease, burns, patient safety and more. One device, multiple clinical software applications. Curiato is post revenue with successful clinical pilots, publications and Health Canada licensed. Curiatio is raising Series A capital to support US market entry, sales & marketing, and creation of additional clinical software applications.

Presenter: Moazam Khan, Co-Founder & CEO

Nuro

NURO is an award-winning start-up from Waterloo, Ontario, which has developed NUOS, the Neural Operating System. With NUOS, incapacitated individuals in various states of Akinetic Mutism (due to Stroke, Trauma or Neurodegeneration) can now communicate and compute using brain signals. NUOS works instantly and without any surgery. NUOS is Health Canada cleared, US IRB cleared and US FDA cleared as the only non-invasive treatment of its kind. NUOS has been released in 3 editions after 6 years of R&D, 5 accelerators in Canada and Silicon Valley and over $1M of funding by SOSV / INDIE BIO, top medical doctors, The Ontario Centres of Excellence and other parties including Canada's FedDev, NRC-IRAP, MaRs, Mitacs, MIT, Google and more.

Presenter: Francois Gand, Founder and CEO

Cardiovascular, Neurodegenerative & CNS DMaura CampbellJanuary 5, 2021

Synmedix

Synmedix is a newly-founded biotechnology company created to commercialize a novel platform that dramatically enhances the effectiveness of antibiotics to address unmet medical need posed by the global health crisis in antibiotic resistance. Synmedix was founded on McMaster University technology, showing that bicarbonate dramatically improves the efficacy and spectrum of several antibiotics enabling the treatment of multidrug-resistant infections. Synmedix is seeking seed funding for preclinical studies leading to an Investigational New Drug (IND) for its lead product BCX-4, azithromycin plus bicarbonate, for a first-in-class treatment of diabetic foot ulcer infections. Clinical development will leverage the FDA’s accelerated 505(b)(2) pathway.

Presenter: Eric Brown, CEO